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     Dopamine, kisspeptin and ghrelin are important factors for regulating the reproduction and food intake. 
Finding the effective central or peripheral factors on ghrelin secretion attracted the attention of most 
researches. In the present experimental study, the effects of dopamine, kisspeptin and the GPR54 receptor 
signaling pathway role in the mediating the dopamine effects  was determined on ghrelin secretion. Forty 
Wistar male rats weighing 220-250g in 8 groups received saline, 1nmol kisspeptin, 5, 15 or 45 microgram 
dopamine hydrochloride, simultaneous injections of 1nmol peptide 234 and kisspeptin, 15microgram 
dopamine and kisspeptin or peptide234 and 15microgram dopamine via third cerebral ventricle 
respectively. Blood samples were collected via tail vein. Mean serum ghrelin concentrations were 
determined by rat ghrelin kit and ELISA method. Kisspeptin significantly decreased mean serum 
concentration compared to saline group, while 15 or 45 microgram dopamine significantly increased mean 
serum ghrelin level compared to saline group. Kisspeptin significantly blocked the stimulatory effects of 
dopamine on ghrelin secretion compared to dopamine group. Dopaminergic and kisspeptin/GPR54 
signaling pathways may interact to control the ghrelin secretion at hypothalamic level. Stimulatory effects 
of dopamine on ghrelin secretions could exert partly via decreasing the activity of hypothalamic kisspeptin 
neurons.  
 
Keywords: peptide234; dopamine; kisspeptin; ghrelin 
 
INTRODUCTION 
     Hypothalamus is a key regulator of a number 
of physiological processes including the 
regulation of feeding behavior, reproduction, and 
different hormones or neurotransmitters secretion. 
Dopamine is a member of catecholamine 
neurotransmitters which is synthesized from 
tyrosine amino acid by the tyrosine hydroxylase 
(TH) and aromatic amino acid decarboxylase 
enzymes. Dopaminergic neurons in different cell 
groups are distributed in the central nervous 
system, especially in the midbrain and 
hypothalamus, projected from these structures to 
several parts of the brain. Hypothalamus contains 
A11 and A12 dopaminergic cell groups which are 
located in the periventricular, posterior, arcuate 
and paraventricular nuclei [1]. Also dopamine is 
synthesized in peripheral organs including 
gastrointestinal, reproductive tracts and so on [2-
3]. It has been found that in addition to 
locomotion, emotion and cognition, dopamine 
regulates several neuroendocrine functions via 
binding to D1-like (receptors D1 and D5) or D2-
like (receptors D2, D3 and D4) receptors [94-5]. 
Kisspeptin is 54 (in human) or 52 (in rodents) 
amino acids neuropeptide which  is synthesized 
by the neurons of hypothalamic nuclei involved 
in the control of food intake and reproduction, 
especially in arcuate nucleus (Arc), and ante-
paraventricular nucleus (PVN) [6]. Kisspeptin 




stimulates reproductive activity via controlling 
gonadotropin releasing hormone (GnRH) 
secretion [7]. However, it suppresses food intake 
response by activating the hypothalamic 
anorexigenic pro-opiomelanocortin (POMC) 
where Kiss1r knock-out animals developed 
obesity [8-10]. Peptide 234(P234) is a 10-amino 
acid synthetic peptide which acts as a kisspeptin 
receptor antagonist named GPR54. It has 
absolutely been established that P234 is able to 
block the kisspeptin influences on reproduction or 
other neuroendocrine axis (7). 
Ghrelin, 28 amino acid peptide is mainly 
synthesized through the stomach and 
hypothalamus nuclei [11]. It is synthesized during 
fasting and acts as endogen ligand for growth 
hormone secretagogues receptor (GHSR-Ia) [11]. 
In addition to increasing food intakes, stimulating 
growth hormone secretion and inhibition 
reproduction process, it plays an important role in 
regulating and pathogenesis of obesity or other 
different  metabolic or endocrinal conditions 
including diabetes, polycystic ovary syndrome 
and so on [11-13]. Recently, controlling ghrelin 
secretion or finding the effective factors involved 
in regulating ghrelin secretion has been the center 
of attention in most researches. Several studies 
try to use its receptor antagonist including D-
Lys
3
- GHRP-6 to prevent or treat obesity and 
other diseases which partly correlate with ghrelin 
signaling pathway.  In the present study, the 
effects of intracerebral ventricular injections of 
kisspeptin10, dopamine hydrochloride and the 
GPR54 receptor signaling pathway role in the 
mediating the dopamine effects  was determined 
on ghrelin secretion. 
 
MATERIALS AND METHODS 
Animals and experimental procedure 
     The present experimental study was performed 
from July to December in Shahid Beheshti 
University of Iran in 2016. Fifty male Wistar rats 
weighing 230- 250g (provided by the Center of 
Neuroscience Research of Shahid Beheshti 
University of Medical Sciences, Iran) were 
housed in the cages under controlled temperature 
(22± 2 C°) and light (12h light/ dark cycle, light 
on 0700h). Animals had free access to food and 
water all the time. All procedures for the 
maintenance and the use of experimental animals 
were approved by Guide for the Care and Use of 
Laboratory Animals (National Institute of Health 
Publication No. 80-23, revised 1996) and were 
approved by the Research and Ethics Committee 
of Shahid Beheshti University of Medical 
Sciences. Following anesthetization via a mixture 
of ketamine and xylezine (ketamine 80 mg/kg 
BW+ xylezine 10 mg/ kg BW), a 22- gauge 
stainless cannula was implanted into third 
cerebral ventricle coordinates (AP = - 2.3, ML=  
0.0, DV=6.5) [14]. After surgery, animals were 
kept in individual cages for one week. Then forty 
rats in 8 groups (n=5 in each group) received 
saline (3µl), kisspeptin (1nmol/3µl), dopamine 
hydrochloride (5, 15 or 45 µg/3µl), kisspeptin 
(1nmol/1.5µl)/peptide234 (1nmol/1.5µl), 
kisspeptin (1nmol/1.5µl)/dopamine hydrochloride 
(15µg/1.5µl) or peptide 234 (1nmol/1.5µl)/ 
dopamine hydrochloride (15µg/ 1.5µl). 
Dopamine hydrochloride (Sigma Aldrich, 
U.S.A.), peptide234 (Phoenix Pharmaceutical Co, 
U.S.A.) and kisspeptin (AnaSpec Co, U.S.A.) 
were dissolved in distilled water and were then  
injected by a 27- gauge stainless steel injector 
through using Hamilton micro syringe via third 
cerebral ventricle at 8:00-9:00. In co-
administrated group peptide, 234 were injected 
10min before dopamine or kisspeptin injections. 
The used drugs doses were selected based on 
previous studies [5, 7, 14].  
Hormone assays  
      Blood samples were collected at 60min 
following injections via tail vein. Blood samples 
centrifuged to 15min at 3000 rpm and the serum 
stored at –20°C until assayed for ghrelin 
concentration. Mean serum ghrelin concentration 
was measured via using rat ghrelin kit (East 
Biopharm Co., China) and the method of enzyme-
linked immunosorbent assay (ELISA). The 
sensitivity of the kit was 25.59ng/L. 
 
STATISTICAL ANALYSIS 
     The results are presented as mean ± SEM. The 
data were analyzed through SPSS software 
(version 16), using one- way ANOVA followed 
by post hoc Tukey test. In all cases, significance 
was defined by p<0.05. 
 





     Mean serum ghrelin levels significantly 
decreased following kisspeptin infusion by 0.33 
times compared to saline (P<0.05, Fig1). During 
simultaneous injection of kisspeptin and P234, 
the mean ghrelin concentration did not 
significantly decline in comparison to saline 
group. On the other hand, the simultaneous 
injection of the two significantly blocked the 
inhibitory effects of kisspeptin on ghrelin 
secretion (P<0.05, Fig1).   Serum ghrelin levels 
was significantly increased by 0.46 times 
following simultaneous injection of kisspeptin 
and P234, compared to only kisspeptin group 
















Figure 1. Effects of third cerebral ventricular injections of 1nmol kisspeptin or simultaneous injections of 1nmol kisspeptine and 
1nmol peptide 234 (P234) on mean serum ghrelin concentration in male wistar rats. *: compared to saline; &: compared to  
kisspeptin (data presented mean ± SEM, P<0.05, n=5 in each group). 
 
Third cerebral ventricular injections 5, 15 or 
45µg of dopamine hydrochloride increased the 
mean serum ghrelin concentration by 0.20, 0. 38 
or 0.69 times compared to saline respectively. 
This decrease was statistically significant 
following 15 or 45µg infusion of dopamine 
compared to saline group (P<0.05, Fig2). Mean 
ghrelin concentration increased 0.15 times 
following injections of 15µg dopamine compared 
to 5µg group while this increase was not 
statistically significant (Fig2). Infusion of 45µg 
dopamine significantly increased the mean 
ghrelin level by 0.23 or 0.40 times compared to 5 














Figure 2. The effects of third cerebral ventricular injections of different doses of dopamine hydrochloride on mean serum ghrelin 
concentration in male wistar rats. *: compared to saline; +: compared to 5µg dopamine; #: compared to 15µg dopamine (data 





























































Kisspeptin significantly decreased the serum 
ghrelin levels by 0.45 times compared to15µg 
dopamine. Simultaneous injection of 1nmol 
kisspeptin and 15µg dopamine increased ghrelin 
level by 0.05 or 0.57 times compared to saline or 
1nmol kisspeptin group respectively. This 
increase was statistically significant only in 
comparison to kisspeptin group (P<0.05, Fig3). 
Also ghrelin levels showed a significant decrease 
(0.24 times) following simultaneous injection of 
1nmol kisspeptin and 15µg dopamine compared 
to only 15µg dopamine group (P<0.05, Fig3). 
Simultaneous injection of 1nmol peptide234 and 
15µg dopamine significantly increased the mean 
ghrelin levels by 0.28, 0.91 or 0.22 times 
compared to saline, 1nmol kisspeptin or 
simultaneous injections of dopamine and 
kisspeptin groups respectively (P<0.05, Fig3). 
While a significant decrease was not observed in 
simultaneous injection of 1nmol peptide234 and 














Figure 3. The effects of third cerebral ventricular injections of dopamine hydrochloride, kisspeptin10, or simultaneous injections of 
kisspeptin and dopamine or simultaneous injections of P234 and dopamine on mean serum ghrelin concentration in male wistar rats. 
*: compared to saline; &: compared to 1nmol kisspeptin; #: compared to 15µg dopamine; $: compared to simultaneous injections of 
kisspeptin and dopamine (data presented mean ± SEM, P<0.05, n=5 in each group). 
 
DISCUSSION 
     The findings showed that the injections of 
dopamine significantly increased mean serum 
ghrelin concentrations compared to control group, 
while kisspeptin significantly decreased mean 
serum ghrelin concentrations compared to control 
group. Ghrelin secretion followed a dose 
response related manner by infusions of different 
doses of dopamine. For the first time, in vivo 
study of dopamine effects was determined on 
ghrelin secretion in male rats. However the 
results are consistent with the only in vitro study 
which reported the stimulatory effects of 
dopamine on ghrelin secretion from mouse 
ghrelinoma3-1 cells (MGN3-1 cells) isolated 
from a gastric ghrelinoma [15]. There are neurons 
in the brain which co-express ghrelin receptor, 
GHSR, and dopamine receptors and infusions of 
ghrelin increases the dopamine D1R-induced 
cAMP accumulation [16-17]. In addition, GHSR 
is expressed in dopaminergic neurons in 
hypothalamus and other parts of central nervous 
system including ventral tegmental area which is 
related to the reward-associated behaviors such as 
food intake [5]. Central injections of different 
dopamine receptor antagonists (D1-like or D2-like 
receptor antagonists) attenuate hypothalamic 
ghrelin pathway and they significantly blocked 
the stimulatory effects of ghrelin on food intakes 
[5]. Likewise, dopamine D1 and D2 receptor 
subtypes are expressed on MGN3-1 cells and 
dopamine D1 receptor antagonists significantly 
decrease the stimulatory influence of dopamine 
on ghrelin secretion [15]. These studies indicate a 
direct interaction between dopamine and ghrelin 
systems in controlling the energy balance and 
food intake. However, indirect intra-neuronal 
pathways might be involved in the mediating 
dopamine action on ghrelin secretion. Insulin is a 
peptide which, in addition to pancreas gland is 
synthesized in central nervous system including 








































exerts inhibitory effects on ghrelin secretions [18-
19].  It has been revealed that dopamine inhibits 
insulin secretion and dopamine receptor knock-
out mice show an increase in plasma insulin 
levels [20]. Consequently, decreasing insulin 
secretion by dopamine injection might be one of 
central mechanisms through which dopamine 
could exert stimulatory effects on ghrelin 
secretion. Based on several previous studies, an 
interaction has been established between ghrelin 
and kisspeptin signaling pathways, in a way that 
central injections of ghrelin regulates 
hypothalamic kisspeptin gene(Kiss1) expression 
in rats [21]. Ghrelin exerts stimulatory effects on 
food intakes while kisspeptin infusion inhibits it 
[9, 11]. The present results showed that the 
secretion of ghrelin was inhibited in kisspeptin 
treated rats. The results are according to the study 
which reports the inhibitory effects of 
intraperitoneal injection of kisspeptin on ghrelin 
secretion [22]. The results exhibited that 
kisspeptin receptor antagonist named peptide234 
significantly blocked the inhibitory influences of 
kisspeptin on ghrelin secretion. It is evident that 
understanding the involved mechanisms in 
controlling the ghrelin secretion by kisspeptin 
needs further studies. However, one could 
suggest that an increase in plasma growth 
hormone (GH) levels following kisspeptin 
injections might be involved in decreasing ghrelin 
neurons activity.  Growth hormone is a peptide 
which is synthesized via somatotroph cells of 
pituitary and in addition to growth effects, it 
plays an important role in regulating the 
metabolism of carbohydrates, proteins and lipids. 
Its synthesis and secretion is mainly controlled by 
hypothalamic growth hormone (GHRH) and 
somatostatin. Different peripheral or central 
neuropeptides, neurotransmitters or hormones 
including ghrelin, kisspeptin, and dopamine 
influence its secretion. Several studies established 
that both ghrelin and kisspeptin infusions 
significantly increase GH secretion [23-24]. And 
increasing plasma GH levels, in turn exerts 
inhibitory effects on ghrelin secretion via a 
negative feedback mechanism [25]. Accordingly, 
an increase in GH secretion following kisspeptin 
injection might be partly involved in the 
mediating its inhibitory effects on ghrelin 
secretions in rats. Recent studies have established 
a close interaction between kisspeptin and 
dopaminergic pathways in regulating several 
neuroendocrine functions such as prolactin or 
gonadotropin releasing hormone, luteinizing 
hormone secretions and the like in different 
animal species. It has been revealed that 
dopaminergic receptors are widely expressed in 
kisspeptin/neurokinin/dynorphin (KNDy neurons) 
neurons [26]. And hypothalamic kisspeptin 
neurons have the ability of highly receiving the 
projections of dopaminergic ones [27-28]. For the 
first time, the present study investigated whether 
dopaminergic pathways might exert stimulatory 
effects on ghrelin secretion by declining 
kisspeptin signaling pathway activity. The results 
demonstrated that mean serum ghrelin 
concentrations significantly decreased following 
the injection of dopamine plus kisspeptin 
compared to dopamine groups while injection of 
GPR54 receptor antagonist significantly 
increased ghrelin secretion compared to 
dopamine plus kisspeptin groups. No previous 
report has focused on the interaction of these 
signaling pathways in controlling ghrelin 
secretion. And further studies are needed to 
determine the exact mechanism involved. 
However, the data of present research 
demonstrated the interference of hypothalamic 
kisspeptin and dopaminergic pathway for 
regulating ghrelin secretion. 
 
CONCLUSION 
     The results revealed that intra-third cerebral 
injections of dopamine hydrochloride 
significantly increased ghrelin secretion in a 
dose-related response while cerebral infusion of 
kisspeptin significantly suppressed its secretion. 
Moreover, the results of blocking the 
kisspeptin/GPR54 signaling pathway suggested 
that dopamine might stimulate ghrelin secretion 
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